Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot2: STU1 Ballot 2) based on FHIR (HL7® FHIR® Standard) v6.0.0. No current official version has been published yet. For a full list of available versions, see the Directory of published versions

Example Group: GLP-1 RA Group in Adults with type 2 diabetes

Page standards status: Informative

Generated Narrative: Group 236948

version: 72; Last updated: 2025-03-20 18:40:09+0000

Profile: ComparatorGroup

Artifact Author: Computable Publishing®: MAGIC-to-FEvIR Converter:

RelatesTo

  • type: part-of
  • targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)

url: https://fevir.net/resources/Group/236948

identifier: FEvIR Object Identifier/https://fevir.net/FOI/236948, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-comparator-85394-C-85798

title: GLP-1 RA Group in Adults with type 2 diabetes

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Glucagon-Like Peptide-1 (GLP-1) receptor agonists

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationComparatorGroup

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

type: Person

membership: Enumerated

combinationMethod: All of

characteristic

code: Member of

value: Adults with type 2 diabetes and CVD and CKD

exclude: false

description:

inclusion in Adults with type 2 diabetes

characteristic

code: Exposed to

value: Glucagon-Like Peptide-1 (GLP-1) receptor agonists

exclude: false

description:

received GLP-1 RA